Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Lamya H. Al-Wahaibi, Anber F. Mohammed, Fatema El-Zahraa S. Abdel Rahman, Mostafa H. Abdelrahman, Xuyuan Gu, Laurent Trembleau & Bahaa G. M. Youssif. (2023) Design, synthesis, apoptotic, and antiproliferative effects of 5-chloro-3- (2-methoxyvinyl)-indole-2-carboxamides and pyrido[3,4-b]indol-1-ones as potent EGFRWT/EGFRT790M inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry 38:1.
Read now
Read now
Amr Sonousi, Rasha A. Hassan, Eman O. Osman, Amr M. Abdou & Soha H. Emam. (2022) Design and synthesis of novel quinazolinone-based derivatives as EGFR inhibitors with antitumor activity. Journal of Enzyme Inhibition and Medicinal Chemistry 37:1, pages 2644-2659.
Read now
Read now
María de Guadalupe Chávez-López, Violeta Zúñiga-García, Elisabeth Hernández-Gallegos, Eunice Vera, Carmen Alexandra Chasiquiza-Anchatuña, Marco Viteri-Yánez, Janet Sanchez-Ramos, Efraín Garrido & Javier Camacho. (2017) The combination astemizole–gefitinib as a potential therapy for human lung cancer. OncoTargets and Therapy 10, pages 5795-5803.
Read now
Read now
Nishant Patel, Pingping Wu & Haijun Zhang. (2017) Comparison of gefitinib as first- and second-line therapy for advanced lung adenocarcinoma patients with positive exon 21 or 19 del epidermal growth factor receptor mutation. Cancer Management and Research 9, pages 243-248.
Read now
Read now
Articles from other publishers (31)
Jagan Mohan Reddy Velidandla & Shiva Kumar Koppula. (2023) Synthesis of Indole-1,3,4-Oxadiazole Based Sulfonyl 1,2,3-Triazoles as Potent Anticancer and EGFR Inhibitors. Russian Journal of Bioorganic Chemistry 49:6, pages 1337-1345.
Crossref
Crossref
Lamya H. Al-Wahaibi, Anber F. Mohammed, Mostafa H. Abdelrahman, Laurent Trembleau & Bahaa G. M. Youssif. (2023) Design, Synthesis, and Biological Evaluation of Indole-2-carboxamides as Potential Multi-Target Antiproliferative Agents. Pharmaceuticals 16:7, pages 1039.
Crossref
Crossref
Praveen Kumar AroraSushil KumarSandeep Kumar Bansal & Prabodh Chander Sharma. (2023) Synthesis, In vitro Cytotoxicity, Molecular docking of Few Quinazolinone Incorporated Naphthyl Chalcones: As Potential Dual Targeting Anticancer Agents to Treat Lung Cancer and Colorectal Cancer. Oriental Journal Of Chemistry 39:2, pages 231-245.
Crossref
Crossref
Xiaotong Song, Luchang Cao, Baoyi Ni, Jia Wang, Xiaoyan Qin, Xiaoyue Sun, Bowen Xu, Xinmiao Wang & Jie Li. (2023) Challenges of EGFR-TKIs in NSCLC and the potential role of herbs and active compounds: From mechanism to clinical practice. Frontiers in Pharmacology 14.
Crossref
Crossref
Lamya H. Al-Wahaibi, Anber F. Mohammed, Mostafa H. Abdelrahman, Laurent Trembleau & Bahaa G. M. Youssif. (2023) Design, Synthesis, and Antiproliferative Activity of New 5-Chloro-indole-2-carboxylate and Pyrrolo[3,4-b]indol-3-one Derivatives as Potent Inhibitors of EGFRT790M/BRAFV600E Pathways. Molecules 28:3, pages 1269.
Crossref
Crossref
Ute Laermann-Nguyen & Wolfgang Kerber. (2023) Ex-Post Analysis of Pharmaceutical Merger Cases in the EU and US: The Identification of the Relevant R&D Projects. SSRN Electronic Journal.
Crossref
Crossref
Kunyu Shi, Guan Wang, Junping Pei, Jifa Zhang, Jiaxing Wang, Liang Ouyang, Yuxi Wang & Weimin Li. (2022) Emerging strategies to overcome resistance to third-generation EGFR inhibitors. Journal of Hematology & Oncology 15:1.
Crossref
Crossref
Rizwan Qureshi, Syed Abdullah Basit, Jawwad A. Shamsi, Xinqi Fan, Mehmood Nawaz, Hong Yan & Tanvir Alam. (2022) Machine learning based personalized drug response prediction for lung cancer patients. Scientific Reports 12:1.
Crossref
Crossref
Sofia Reis Brandão, Félix Carvalho, Francisco Amado, Rita Ferreira & Vera Marisa Costa. (2022) Insights on the molecular targets of cardiotoxicity induced by anticancer drugs: A systematic review based on proteomic findings. Metabolism 134, pages 155250.
Crossref
Crossref
Ryuichi Ono, Yusuke Yoshioka, Yusuke Furukawa, Mie Naruse, Makiko Kuwagata, Takahiro Ochiya, Satoshi Kitajima & Yoko Hirabayashi. 2022. Genomic and Epigenomic Biomarkers of Toxicology and Disease. Genomic and Epigenomic Biomarkers of Toxicology and Disease
37
62
.
Matt Shirley & Susan J. Keam. (2022) Aumolertinib: A Review in Non-Small Cell Lung Cancer. Drugs 82:5, pages 577-584.
Crossref
Crossref
Bing Liu, Daniela Duenas, Li Zheng, Karen Reckamp & Binghui Shen. (2021) Genomic instability as a major mechanism for acquired resistance to EGFR tyrosine kinase inhibitors in cancer. Protein & Cell 13:2, pages 82-89.
Crossref
Crossref
J. Machado-Rugolo, C.M. Baldavira, T.G. Prieto, E.H.R. Olivieri, A.T. Fabro, C.A. Rainho, E.C. Castelli, P.E.M. Ribolla, A.M. Ab'Saber, T. Takagaki, M.A. Nagai & V.L. Capelozzi. (2022) Clinical outcome of Brazilian patients with non-small cell lung cancer in early stage harboring rare mutations in epidermal growth factor receptor. Brazilian Journal of Medical and Biological Research 55.
Crossref
Crossref
Fatma A.M. Mohamed, Hesham A.M. Gomaa, O.M. Hendawy, Asmaa T. Ali, Hatem S. Farghaly, Ahmed M. Gouda, Ahmed H. Abdelazeem, Mostafa H. Abdelrahman, Laurent Trembleau & Bahaa G.M. Youssif. (2021) Design, synthesis, and biological evaluation of novel EGFR inhibitors containing 5-chloro-3-hydroxymethyl-indole-2-carboxamide scaffold with apoptotic antiproliferative activity. Bioorganic Chemistry 112, pages 104960.
Crossref
Crossref
Surya Kant Tripathi & Bijesh K. Biswal. (2021) Allosteric mutant-selective fourth-generation EGFR inhibitors as an efficient combination therapeutic in the treatment of non-small cell lung carcinoma. Drug Discovery Today 26:6, pages 1466-1472.
Crossref
Crossref
Christopher Woodman, Gugulethu Vundu, Alex George & Cornelia M. Wilson. (2021) Applications and strategies in nanodiagnosis and nanotherapy in lung cancer. Seminars in Cancer Biology 69, pages 349-364.
Crossref
Crossref
Barbara Melosky, Parneet Cheema, Rosalyn A. Juergens, Natasha B. Leighl, Geoffrey Liu, Paul Wheatley-Price, Adrian Sacher, Stephanie Snow, Ming-Sound Tsao, Deanna McLeod & Quincy Chu. (2021) The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer. Therapeutic Advances in Medical Oncology 13, pages 175883592110563.
Crossref
Crossref
Eric Nadler, Melissa Pavilack, Janet L. Espirito, Jamyia Clark & Ancilla Fernandes. (2020) Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors. Advances in Therapy 37:2, pages 946-954.
Crossref
Crossref
Mohamed Reda Aouad, Hannan Musallam Al-Mohammadi, Fawzia Faleh Al-blewi, Saleh Ihmaid, Hossein Mostafa Elbadawy, Sultan Saad Althagfan & Nadjet Rezki. (2020) Introducing of acyclonucleoside analogues tethered 1,2,4-triazole as anticancer agents with dual epidermal growth factor receptor kinase and microtubule inhibitors. Bioorganic Chemistry 94, pages 103446.
Crossref
Crossref
Chathura Siriwardhana, Vedbar S. Khadka, John J. Chen & Youping Deng. (2019) Development of a miRNA-seq based prognostic signature in lung adenocarcinoma. BMC Cancer 19:1.
Crossref
Crossref
Ayano Oashi, Hiroyuki Yasuda, Keigo Kobayashi, Tetsuo Tani, Junko Hamamoto, Keita Masuzawa, Tadashi Manabe, Hideki Terai, Shinnosuke Ikemura, Ichiro Kawada, Katsuhiko Naoki & Kenzo Soejima. (2019) Monomer Preference of EGFR Tyrosine Kinase Inhibitors Influences the Synergistic Efficacy of Combination Therapy with Cetuximab. Molecular Cancer Therapeutics 18:9, pages 1593-1601.
Crossref
Crossref
David M. Evans, Jianwen Fang, Thomas Silvers, Rene Delosh, Julie Laudeman, Chad Ogle, Russell Reinhart, Michael Selby, Lori Bowles, John Connelly, Erik Harris, Julia Krushkal, Larry Rubinstein, James H. Doroshow & Beverly A. Teicher. (2019) Exposure time versus cytotoxicity for anticancer agents. Cancer Chemotherapy and Pharmacology 84:2, pages 359-371.
Crossref
Crossref
Romeo Romagnoli, Filippo Prencipe, Paola Oliva, Stefania Baraldi, Pier Giovanni Baraldi, Santiago Schiaffino Ortega, Mariem Chayah, Maria Kimatrai Salvador, Luisa Carlota Lopez-Cara, Andrea Brancale, Salvatore FerlaErnest Hamel, Roberto Ronca, Roberta Bortolozzi, Elena Mariotto, Elena Mattiuzzo & Giampietro Viola. (2019)
Design, Synthesis, and Biological Evaluation of 6-Substituted Thieno[3,2-
d
]pyrimidine Analogues as Dual Epidermal Growth Factor Receptor Kinase and Microtubule Inhibitors
. Journal of Medicinal Chemistry 62:3, pages 1274-1290.
Crossref
Crossref
Rashmi R. Shah & Devron R. Shah. (2019) Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology. Drug Safety 42:2, pages 181-198.
Crossref
Crossref
Stefano Fogli, Beatrice Polini, Marzia Del Re, Iacopo Petrini, Antonio Passaro, Stefania Crucitta, Eleonora Rofi & Romano Danesi. (2018) EGFR-TKIs in non-small-cell lung cancer: focus on clinical pharmacology and mechanisms of resistance. Pharmacogenomics 19:8, pages 727-740.
Crossref
Crossref
E N Lyukmanova, M L Bychkov, G V Sharonov, A V Efremenko, M A Shulepko, D S Kulbatskii, Z O Shenkarev, A V Feofanov, D A Dolgikh & M P Kirpichnikov. (2018)
Human secreted proteins
SLURP‐1
and
SLURP‐2
control the growth of epithelial cancer cells
via
interactions with nicotinic acetylcholine receptors
. British Journal of Pharmacology 175:11, pages 1973-1986.
Crossref
Crossref
Tsatsral Iderzorig, Joseph Kellen, Chike Osude, Sanjana Singh, James A. Woodman, Christian Garcia & Neelu Puri. (2018) Comparison of EMT mediated tyrosine kinase inhibitor resistance in NSCLC. Biochemical and Biophysical Research Communications 496:2, pages 770-777.
Crossref
Crossref
Peihe Wang, Yuanyuan Cai, Dongju Lin & Yingxiao Jiang. (2017) Gamma Irradiation Upregulates B-cell Translocation Gene 2 to Attenuate Cell Proliferation of Lung Cancer Cells Through the JNK and NF-B Pathways. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 25:7, pages 1199-1205.
Crossref
Crossref
Xing Ke & Lisong Shen. (2017) Molecular targeted therapy of cancer: The progress and future prospect. Frontiers in Laboratory Medicine 1:2, pages 69-75.
Crossref
Crossref
Adouda Adjiri. (2017) DNA Mutations May Not Be the Cause of Cancer. Oncology and Therapy 5:1, pages 85-101.
Crossref
Crossref
Laura E. Hanold, Melody D. Fulton & Eileen J. Kennedy. (2017) Targeting kinase signaling pathways with constrained peptide scaffolds. Pharmacology & Therapeutics 173, pages 159-170.
Crossref
Crossref